Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

U.S. stocks appear set to open on a weak note on Monday as Iran’s Parliament voted to block the Strait of Hormuz in ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...